Theorem Clinical Research

Drug Sponsors

Celsion completes acquisition of Egen

Friday, June 20, 2014 01:04 PM

Celsion, an oncology drug development company, has completed its acquisition of substantially all of the assets of Egen, a privately held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. The acquisition includes Egen’s phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas for delivery of DNA and mRNA, TheraSilence for delivery of RNA and RAST for Cell Enabled Expression and Secretion of RNA.

More... »


SillaJen Biotherapeutics completes name change

Friday, June 20, 2014 01:01 PM

SillaJen, a privately held biotherapeutics company focused on development of targeted oncolytic immunotherapy products for cancer, has completed its name change to SillaJen Biotherapeutics following its acquisition of Jennerex Biotherapeutics.

More... »


Pfizer opens new R&D site in Cambridge, Mass.

Tuesday, June 17, 2014 11:08 AM

Pfizer has announced the opening of a new 280,000-square-foot R&D hub in Cambridge, Mass. The new Pfizer facilities in Kendall Square bring together 1,000 colleagues from three area locations and positions Pfizer in closer proximity to leading academic institutions, hospitals and patient organizations.

More... »

Medtronic to acquire Covidien for $42.9 billion

Monday, June 16, 2014 09:43 AM

Medtronic, a global medical technology, services and solutions company, has agreed to acquire Covidien, a global healthcare technology and medical supplies provider, in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9 billion, based on Medtronic’s closing stock price of $60.70 per share on June 13. 

More... »

EntreMed stockholders approve name change to CASI Pharmaceuticals

Friday, June 13, 2014 01:13 PM

EntreMed, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other diseases, said its annual meeting of stockholders voted in favor of changing the company's corporate name to CASI Pharmaceuticals. The name change will occur June 16, with the rollout of a new web site, www.casipharmaceuticals.com.

More... »

Novo Nordisk to add 6,000 new jobs in Denmark by 2022

Friday, June 13, 2014 01:10 PM

Global healthcare company Novo Nordisk expects to hire 6,000 new employees in Denmark through 2022, half of whom will work within R&D. According to a Novo Nordisk report, the new jobs will have the derived effect of boosting employment by more than 15,000 jobs nationally.

More... »

Cardiovascular Systems plans new corporate headquarters

Friday, June 13, 2014 01:07 PM

Cardiovascular Systems, a medical device company, has plans to build a new corporate headquarters in New Brighton, Minn. The 125,000-square-foot, two-story building will have space for more than 500 employees and contain dedicated R&D, training and education and manufacturing facilities. CSI’s headquarters will be located in the New Brighton Exchange, approximately 10 minutes from downtown Minneapolis.

More... »

TeraDiscoveries changes name to Cloud Pharmaceuticals

Thursday, June 12, 2014 01:38 PM

TeraDiscoveries, a bio-therapeutics company focused on cloud-based drug design and development, has changed its corporate name to Cloud Pharmaceuticals.

More... »

Allergan board unanimously rejects revised Valeant proposal

Wednesday, June 11, 2014 12:54 PM

Allergan’s board of directors has unanimously determined the revised unsolicited proposal by Pershing Square and Valeant Pharmaceuticals International substantially undervalues the company, creates significant risks and uncertainties for the stockholders of Allergan and is not in the best interests of the company and its stockholders.

More... »

Celsion to acquire Egen

Wednesday, June 11, 2014 12:48 PM

Celsion, an oncology drug development company, and Egen, a privately held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, have signed a definitive asset purchase agreement for Celsion to acquire substantially all of Egen’s assets, including its phase Ib DNA-based immunotherapy product candidate Egen-001 and its therapeutic platform technologies, TheraPlas for delivery of DNA and mRNA, TheraSilence for delivery of RNA and RAST for Cell Enabled Expression and Secretion of RNA.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs